Alliances
MorphoSys AG and Incyte Corporation announced that the companies have entered into a collaboration and license agreement to further develop and commercialize MorphoSys’ proprietary anti-CD19 antibody tafasitamab globally.
MorphoSys AG announces that it has entered into a global collaboration and licensing agreement with Incyte Corporation to further develop and commercialize MorphoSys’ proprietary anti-CD19 antibody tafasitamab.
First collaboration project focused on developing and commercializing lentiviral manufacturing system
With a shared vision to be a catalyst for Canadian life sciences leading the world, adMare BioInnovations, Canada’s Global Life Sciences Venture, and Accel-Rx, Canada’s Health Sciences Accelerator, announced they are bringing their respective capabilities and resources together under adMare to create a world leading organization.
Exscientia, the leading Artificial Intelligence -driven drug discovery company, announced today that it has entered a collaboration with Bayer AG that aims to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.
What’s New at the J.P. Morgan Life Healthcare Conference?
Gilead Sciences is boosting support for a Bay Area startup looking to develop a new class of therapies for autoimmune diseases.
Charles River will use its strengths to help develop potential drug candidates across Takeda’s four core therapeutic areas—oncology, gastroenterology, neuroscience and rare disease.
Helen Tayton-Martin, Adaptimmune’s chief business officer and co-founder, said the partnership with Astellas builds upon and extends an existing collaboration focused on gene editing of iPSC cells.
The deal will increase the availability of next-generation sequencing-based in vitro diagnostic (IVD) tests on Illumina’s diagnostic sequencing systems.
PRESS RELEASES